Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 7Colorectal Neoplasms 6Neoplasms 4Neoplasm Metastasis 4Colonic Neoplasms 4Pancreatic Neoplasms 3Lung Neoplasms 2Carcinoma, Renal Cell 2Advanced Solid Tumor 2Kidney Neoplasms 1Healthy Adults 1

Interventions

Gemcitabine 170130-nm albumin-bound paclitaxel 54Albumin-Bound Paclitaxel 42Oxaliplatin 33Fluorouracil 32pembrolizumab 30Capecitabine 30Leucovorin 28Irinotecan 28Radiotherapy 25Nivolumab 22Erlotinib Hydrochloride 21Taxes 19Cisplatin 19Bevacizumab 15Magnetic Resonance Spectroscopy 13Specimen Handling 12Radiosurgery 11Ipilimumab 11Cyclophosphamide 11Drug Therapy 10Carboplatin 10Biopsy 10Paclitaxel 9Docetaxel 9Cetuximab 9trametinib 8olaparib 8durvalumab 8Sorafenib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Pancreatic Neoplasms × adagrasib × Clear all
NCT05634525 2025-07-25

Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients

M.D. Anderson Cancer Center

Phase 1 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

NCT04330664 2025-04-04

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

Mirati Therapeutics Inc.

Phase 1 Completed
86 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04975256 2024-12-16

Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)

Mirati Therapeutics Inc.

Phase 1 Terminated
7 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡